News Archives - Lyell
bm-navigation: bm-t3-home-navigation
bm-pageheader: bm-t3-pageheader

CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series A Financing

Press release from CERo Therapeutics Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors $40 Million Raised by CERo to Facilitate Preclinical and Clinical Development South San Francisco, Calif. – March 18, 2020 – CERo Therapeutics, Inc., a privately held biopharmaceutical company, today announced a research collaboration with Lyell Immunopharma, Inc. to develop … Continued

EUREKA THERAPEUTICS COMPLETES $45 MILLION SERIES E FINANCING AND ENTERS INTO STRATEGIC COLLABORATION WITH LYELL IMMUNOPHARMA

Press release from Eureka Therapeutics Emeryville, California, March 17, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies for solid tumors, today announced that it has closed a $45 million Series E financing. The round was led by Lyell Immunopharma and joined by a syndicate of new and prior … Continued

GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies

Press release from GSK Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability Issued: London and San Francisco GlaxoSmithKline plc today announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer patients. The collaboration will apply Lyell’s technologies … Continued